{
    "nct_id": "NCT00024531",
    "title": "Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2006-11-08",
    "description_brief": "The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.",
    "description_detailed": "This study is a phase II, placebo controlled, double-blind, one year trial investigating the effect of HmG-CoA reductase inhibitor atorvastatin calcium in the treatment of persons with possible or probable Alzheimer's disease. Subjects may continue to take stable doses of Aricept and Exelon. Following enrollment, participants will make visits to the study center every three months for blood tests and neuropsychological testing.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Atorvastatin (Lipitor)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention named in the trial is Lipitor (atorvastatin calcium), a marketed HMG-CoA reductase inhibitor (a small-molecule statin) used to lower cholesterol. The study title and brief description state the purpose is to assess clinical benefit of atorvastatin in Alzheimer's disease, i.e., a pharmacologic treatment intervention rather than a diagnostic or non-therapeutic procedure. \ue200cite\ue202turn0search6\ue202turn0search4\ue201",
        "Act (key extracted details): Trial title and registration: \u201cEffect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease\u201d (NCT00024531), described as a Phase 2, placebo-controlled, double-blind, one-year trial assessing Lipitor in persons with possible or probable Alzheimer\u2019s disease. The intervention is atorvastatin; a placebo control was used. \ue200cite\ue202turn0search6\ue201",
        "Act (mechanism / prior evidence): Atorvastatin is a small-molecule HMG-CoA reductase inhibitor (statin) that lowers circulating cholesterol. Statins have been hypothesized to influence Alzheimer pathology via cholesterol-related effects on amyloid-beta production/processing; clinical trials have tested this repurposing. Pilot and subsequent randomized trials have reported mixed results (some early pilot signals, but larger trials found no significant clinical benefit). \ue200cite\ue202turn0search4\ue202turn0search3\ue202turn0search0\ue201",
        "Reflection / category choice: By the definitions provided: (1) Disease-targeted biologic \u2014 biologic therapies (e.g., antibodies, vaccines) targeting AD pathology; (2) Disease-targeted small molecule \u2014 small-molecule drugs targeting AD pathology; (3) Cognitive enhancer \u2014 symptomatic cognitive agents without disease-pathology targeting; (4) Neuropsychiatric symptom improvement \u2014 behavioral/psychiatric symptom treatments. Atorvastatin is a small-molecule drug (statin). Although its primary pharmacologic target is cholesterol synthesis (HMG-CoA reductase) and not directly amyloid or tau, the trial tests atorvastatin as a disease-modifying/therapeutic agent for Alzheimer\u2019s disease (repurposing based on cholesterol\u2013amyloid biology). Therefore the best-fit category is: disease-targeted small molecule. I note ambiguity: it is not a biologic and not primarily described as a symptomatic cognitive enhancer or as a neuropsychiatric-targeted agent; its proposed disease effect is indirect via lipid biology. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Web search results / supporting sources (selected):\n- Clinical trial registration (NCT00024531) \u2014 trial title and brief description confirming Lipitor/atorvastatin in AD; Phase 2, placebo-controlled, 1-year. \ue200cite\ue202turn0search6\ue201\n- Pilot randomized trial / ADCLT results \u2014 single-site pilot showed a positive signal on ADAS-cog at 6 months in a small study of atorvastatin 80 mg vs placebo. \ue200cite\ue202turn0search3\ue202turn0search5\ue201\n- Larger multicenter LEADe randomized trial (atorvastatin 80 mg/day) \u2014 no significant benefit on cognition or global function over 72 weeks. \ue200cite\ue202turn0search0\ue202turn0search1\ue201\n- Overview / safety profile of atorvastatin (Lipitor) describing its mechanism as an HMG-CoA reductase inhibitor (statin). \ue200cite\ue202turn0search4\ue201\n- Systematic review of atorvastatin for AD summarizing randomized trial data. \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "C) ApoE, Lipids and Lipoprotein Receptors",
    "explanation_agent": [
        "Reason: The intervention is atorvastatin (Lipitor), a small-molecule HMG-CoA reductase inhibitor (a statin) whose primary pharmacologic action is to lower cholesterol and alter lipid metabolism. The trial tests atorvastatin as a disease-directed therapy for Alzheimer\u2019s disease based on lipid\u2013amyloid biology. This aligns most specifically with CADRO category C (ApoE, Lipids and Lipoprotein Receptors), which covers lipid biology and apolipoprotein-related mechanisms. \ue200cite\ue202turn0search2\ue202turn0search5\ue201",
        "Act: Key extracted details from the trial description and literature \u2014 drug: atorvastatin (Lipitor); mechanism: competitive inhibition of HMG-CoA reductase \u2192 reduced cholesterol biosynthesis / altered lipoprotein biology; trial: Phase 2, placebo-controlled study (NCT00024531) titled \u201cEffect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease.\u201d These facts support mapping the target to lipid/ApoE-related CADRO domain. \ue200cite\ue202turn1search1\ue202turn0search6\ue201",
        "Reflect: Confirming the best-fit CADRO category \u2014 although atorvastatin\u2019s primary molecular target is the metabolic enzyme HMG-CoA reductase (which could be seen as a metabolic target), the therapeutic hypothesis in AD concerns modulation of cholesterol/lipoprotein biology (and interactions with ApoE and amyloid processing). CADRO C (ApoE, Lipids and Lipoprotein Receptors) is the most specific and appropriate category; J (Metabolism and Bioenergetics) would be a broader alternative but less specific for lipid/ApoE-focused AD hypotheses. Supporting trial outcomes and context: pilot ADCLT showed a short-term signal, while the larger LEADe trial found no significant cognitive benefit \u2014 these confirm the intervention\u2019s lipid-focused mechanism and its evaluation in AD. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Output: {\"category\": \"C) ApoE, Lipids and Lipoprotein Receptors\"}",
        "Supporting web search sources:",
        "- Clinical trial registration / record for NCT00024531 (Lipitor as a Treatment for Alzheimer's Disease). \ue200cite\ue202turn1search1\ue202turn1search0\ue201",
        "- Atorvastatin mechanism and pharmacology (HMG-CoA reductase inhibitor / statin). \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "- Pilot ADCLT trial reporting short-term ADAS-cog signal. \ue200cite\ue202turn0search5\ue201",
        "- Large randomized LEADe trial (multicenter) showing no significant benefit of atorvastatin in mild\u2013moderate AD. \ue200cite\ue202turn0search0\ue202turn0search1\ue201"
    ]
}